PedAM
Pediatric Disease Annotations & Medicines
| Disease | vascular disease |
| Phenotype | |type 2 diabetes |
| Sentences | 223 |
| PubMedID- 25018969 | Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 21411509 | A mild-to-moderate reduction of egfr predicts cardiovascular disease in patients with type 2 diabetes, also independently of classic risk factors (24). |
| PubMedID- 22305579 | Conclusions: time-dependent variation of fpg was a strong predictor of all-cause, expanded, and nonexpanded cardiovascular disease-related mortality in patients with type 2 diabetes, suggesting that glucose variation may become a measure in clinical practice for the goal in the management of these patients. |
| PubMedID- 22871895 | Conclusion: bp around 130-135/75-79 mmhg showed lower risks of cardiovascular diseases in patients with type 2 diabetes. |
| PubMedID- 20431592 | We aimed this study to test the hypotheses that heart rate (hr) variability, evaluated by ambulatory blood pressure monitoring (abpm), predicts risk of incident cardiovascular disease (cvd) in patients with type 2 diabetes (t2dm). |
| PubMedID- 25214836 | Left ventricular hypertrophy (lvh) and albuminuria are both markers for cardiovascular diseases (cvds) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 26312908 | Interpretation: this study suggests that associations of type 2 diabetes vary with different incident cardiovascular diseases. |
| PubMedID- 26078978 | The presence of macrovascular disease in patients with type 2 diabetes may be a confounding factor when assessing an association of vitamin d with other conditions. |
| PubMedID- 21073045 | Paraoxonase 1 activity as a predictor of cardiovascular disease in type 2 diabetes. |
| PubMedID- 23913590 | Pediatric cancer survivors have increased risk of obesity, hypertension, dyslipidemia, and type 2 diabetes, leading to premature cardiovascular disease (cvd). |
| PubMedID- 23119148 | In the advance trial, the effect of intensive blood pressure control on cardiovascular disease in patients with long standing type 2 diabetes at high risk for vascular disease was studied. |
| PubMedID- 19859073 | The burden of microvascular disease in patients with type 2 diabetes mellitus continues to escalate worldwide. |
| PubMedID- 24076532 | (presence of macrovascular disease in type 2 diabetes mellitus; nct00298844). |
| PubMedID- 21080957 | Therefore, based on the findings from the present study and the accumulating body of clinical evidence with exenatide, therapy with glp-1 receptor agonists may represent a promising approach for the treatment of patients with chf or cardiovascular disease associated with type 2 diabetes, supporting the need for further research in this field. |
| PubMedID- 20634718 | Systolic blood pressure and risk of cardiovascular diseases in type 2 diabetes: an observational study from the swedish national diabetes register. |
| PubMedID- 21933841 | Purpose: to evaluate myocardial microvascular disease in patients with type 2 diabetes mellitus (dm) using myocardial contrast echocardiography (mce) and to report on its diagnostic accuracy using single photon emission tomography (spect) as reference test. |
| PubMedID- 24624891 | Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (riace) italian multicenter study. |
| PubMedID- 19232762 | Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. |
| PubMedID- 22111049 | However, the relationships between dpn and cardiovascular disease (cvd) outcomes in patients with type 2 diabetes have not been fully investigated. |
| PubMedID- 23829205 | Hemoglobin a1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (riace) italian multicenter study. |
| PubMedID- 25027342 | Blood glucose fluctuation aggravates lower extremity vascular disease in type 2 diabetes. |
| PubMedID- 25191571 | Dietary strategies for alleviating health complications, such as premature vascular disease,associated with type 2 diabetes (t2d) and obesity are actively being pursued as alternativesto pharmaceutical interventions(1). |
| PubMedID- 23463747 | Risk association of hba1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the hong kong diabetes registry. |
| PubMedID- 25813675 | Objectives: the prevalence of atherosclerotic cardiovascular disease is increased in patients with type 2 diabetes. |
| PubMedID- 20822519 | Contradictory results have also been published regarding the role of fetuin-a in macrovascular disease and patients with type 2 diabetes [12-14]. |
| PubMedID- 24918803 | Interventions targeted at modifiable risk factors, such as smoking cessation and management of hypertension and dyslipidemia, reduce the risk of cardiovascular disease (cvd) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 25762229 | The ugdp trial was an open-label, prospective, five-armed, rct that was designed in 1961 to evaluate the effects of different hypoglycaemic treatments on vascular disease in patients with type 2 diabetes. |
| PubMedID- 23008738 | However, the results varied by population (healthy adults, adults at cardiovascular disease risk, adults with type 2 diabetes, etc.) |
| PubMedID- 22827292 | Although large clinical trials are required to confirm these beneficial effects, glucagon-like peptide-1-based therapy could provide both glucose lowering and protection against cardiovascular diseases in patients with type 2 diabetes. |
| PubMedID- 22338075 | Associations between exponential childhood growth superimposed on low birth weight and adult onset cardiovascular disease with glucose intolerance/type 2 diabetes mellitus exist in epidemiological investigations. |
| PubMedID- 24843669 | A previous clinical randomized trial clearly showed that atorvastatin, an inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase, reduces the incidence of cardiovascular disease in patients with type 2 diabetes1. |
| PubMedID- 22210236 | Objective: depression in type 2 diabetes is associated with obesity, cardiovascular disease, and mortality. |
| PubMedID- 26083376 | Pioglitazone has shown to have beneficial effect on cardiovascular diseases in patients with type 2 diabetes mellitus [18–20]. |
| PubMedID- 20929995 | Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (glp-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the lifelink database. |
| PubMedID- 21934489 | Although perturbations of haemostatic markers have been shown to be associated with macrovascular disease in patients with type 2 diabetes, it is unclear whether these are primarily due to endothelial dysfunction or a result of inflammation. |
| PubMedID- 24186881 | Genetic and environmental determinants of dimethylarginines and association with cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 24452874 | Prevention of macrovascular disease in patients with short-duration type 2 diabetes by multifactorial target control: an 8-year prospective study. |
| PubMedID- 26042596 | Therefore, nafld may result in an increased risk of mortality, especially due to cardiovascular disease, in patients with type 2 diabetes. |
| PubMedID- 23772277 | Atherosclerotic cardiovascular disease among patients with type 2 diabetes in basrah. |
| PubMedID- 25539939 | Abnormally elevated postprandial glucose and triacylglycerol (tag) concentrations are risk factors for cardiovascular disease in type 2 diabetes. |
| PubMedID- 20550659 | The action to control cardiovascular risk in diabetes (accord) study investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus. |
| PubMedID- 22115901 | Observational studies suggest an association between the extent of hyperglycaemia and the risk of death and of macrovascular and microvascular disease in patients with type 2 diabetes.1 2 3 three recent randomised clinical trials in patients with type 2 diabetes were not able to detect (or reject the possibility of) reduced cardiovascular disease or mortality with intensive compared with conventional glycaemic control.4 5 6 worries arose as the results from the action to control cardiovascular risk in diabetes (accord) trial in 2008 showed increased all cause mortality and cardiovascular mortality in the intensive treatment group compared with conventional treatment.4 the increased mortality led to early termination of the accord trial.4 on the other hand, randomised clinical trials have indicated a beneficial effect on microvascular complications of intensive versus conventional glycaemic control in patients with type 2 diabetes. |
| PubMedID- 23953177 | Objectives: to determine the risk factors for cardiovascular disease among patients with type 2 diabetes. |
| PubMedID- 26399335 | The aim of the present study was to evaluate association between af value and diabetic vascular complications, such as retinopathy, nephropathy and cervical atherosclerosis using the carotid intima-media thickness (imt), an established marker of cardiovascular disease in patients with type 2 diabetes. |
| PubMedID- 26244041 | A recent review identified twelve risk equations for the prediction of cardiovascular disease in subjects with type 2 diabetes mellitus (t2dm) [6]. |
| PubMedID- 22247898 | Intensive blood glucose control decreases the risk of developing microvascular complications but not macrovascular disease in patients with type 2 diabetes. |
| PubMedID- 22891848 | Objectives: hypertension and proteinuria are major risk factors for cardiovascular disease (cvd) mortality in patients with type 2 diabetes. |
| PubMedID- 24651718 | Glp-1 receptor agonist represents a novel approach for the treatment of patients with cardiovascular disease associated with type 2 diabetes [28]. |
| PubMedID- 22430605 | In view of the high incidence of macrovascular diseases in patients with type 2 diabetes mellitus and microalbuminuria, the study evaluates the association of microalbuminuria with fasting plasma apo b48 levels, a marker of the residual presence of intestinally derived trls lipoproteins, thought to be highly atherogenic. |
| PubMedID- 21963093 | Clinical intervention studies are needed to clarify whether treatment with vitamin d decreases the risk of cardiovascular disease in patients with type 2 diabetes. |